Keenova Presents New Data on TERLIVAZ for Hepatorenal Syndrome

The findings, presented by Dr. Nancy Reau of Rush University Medical Center, aim to address clinical gaps for individuals suffering from this rapidly progressive and life-threatening complication of advanced liver disease. TERLIVAZ remains the only FDA-approved therapy designed to improve kidney function in these specific adult populations. According to the research team, the data provides providers with further evidence to support care strategies for patients facing restricted transplant options.

Hepatorenal syndrome-acute kidney injury is an urgent medical emergency that has seen a marked rise in prevalence, with national data indicating that the number of inpatient diagnoses climbed from 42,930 to 63,381 between 2018 and 2023. While the therapy offers a critical intervention, medical professionals are cautioned regarding its use, particularly given the risk of respiratory failure and ischemic events. The prescribing information includes a boxed warning, noting that the drug is contraindicated in patients with hypoxia or those experiencing significant respiratory symptoms.